PT  - JOURNAL ARTICLE
AU  - Chillon, Alberto
AU  - Pace, Arianna
AU  - Zuccato, Daniele
TI  - Introducing the Alba® Primary Packaging Platform. Part 1: Particle Release Evaluation
AID  - 10.5731/pdajpst.2018.008623
DP  - 2018 Jan 01
TA  - PDA Journal of Pharmaceutical Science and Technology
PG  - pdajpst.2018.008623
4099  - http://journal.pda.org/content/early/2018/05/25/pdajpst.2018.008623.short
4100  - http://journal.pda.org/content/early/2018/05/25/pdajpst.2018.008623.full
AB  - The sensitivity of drugs to one or more elements of the primary packaging is a serious concern for the pharmaceutical industry. Biologics in particular are highly sensitive, leading to a higher risk of incompatibility and stability test failures as worst case scenario. This potential incompatibility - and the consequent formulation instability due to the interactions between the drug and the primary container surface - may have multiple causes: the intrinsic nature of the container surface, leachables coming from the materials used, substances coming from the production process, silicone oil droplets or other particles. The Alba primary packaging platform was designed in order to have the same interface between the drug and the glass container surface on the different primary packaging containers to minimize the emergence of instabilities at later stages during the formulation development. The Alba containers are internally treated with an innovative cross-linked coating based on silicone oil lubricant and the additional rubber components have been selected to minimize the possible differences between the container typologies. This paper shows in deep details the subvisible particle release reduction and the comparability of the performances of different containers, obtained using such technology. To demonstrate this improvement, different analytical methods for particle measurement were used on bulk containers, Alba treated ones and containers from a standard production (spray-on siliconization). Considering that Alba containers are conform to the standard compendial testing and the amount of particles released from Alba coated syringes resulted comparable to the bulk ones for the first two mildly stressful methods, it was decided to develop and apply a more challenging method, such as an autoclave treatment for 1 hour at 121°C, to better highlight the performances of this innovative technology. The data obtained, under the most stressful conditions, shows a substantial reduction in the released particle concentrations compared to a spray-on siliconized container, and comparable performances for all the containers included in the Alba platform. The latter could heavily reduce the drug formulation development timings, facilitating the transition from a container to another.